Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
30 mai 2023 07h30 HE
|
Aclarion, Inc.
The London Clinic is the UK’s most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997. The London...
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
23 mai 2023 07h30 HE
|
Aclarion, Inc.
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy Aclarion to Participate in...
Aclarion, Inc. Announces Delayed 10-Q Filing
23 mai 2023 07h00 HE
|
Aclarion, Inc.
BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
19 mai 2023 07h30 HE
|
Aclarion, Inc.
Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of...
Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain
02 mai 2023 07h00 HE
|
Aclarion, Inc.
Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market,...
Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023
28 avr. 2023 11h20 HE
|
Aclarion, Inc.
Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain. Nociscan provides decision support to help bridge a...
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
24 avr. 2023 07h00 HE
|
Aclarion, Inc.
Success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over...
Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor
07 mars 2023 09h19 HE
|
Aclarion, Inc.
Marks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023 Broomfield,...
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
15 févr. 2023 07h00 HE
|
Aclarion, Inc.
NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a...
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
31 janv. 2023 10h01 HE
|
Aclarion, Inc.
Director of Endoscopic Spine Surgery at the University of Miami Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq:...